Boston Scientific Receives FDA Clearance for Avvigo+ Multimodal Guidance System

Sep 29, 2023 00:00 CST Updated 00:00

Boston Scientific

Medical Device Manufacturer

Source of the article:Heart NotCome;Editor:Huang Chuyan

Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.

Heart Future

On September 27, 2023, Boston Scientific Corporation (NYSE: BSX) announced,Its Avvigo+ Multimodal Guidance System has received FDA clearance.

# Avvigo+ Multimodal Guidance System Receives FDA Approval

Avvigo+ Multimodal Guidance SystemProvide Intravascular Ultrasound（IVUS）And Fractional Flow Reserve（FFR) technology,It uses advanced software and hardware to provide high-qualityIVUSVascular Imaging.ItsUses include percutaneous coronary intervention (PCI) Surgery.

TheThe technology, based on the company's Avvigo Guidance System II, provides information for treatment decisions.It can provide faster and more effective surgeries for patients with coronary artery disease, such as angioplasty and atherectomy.

BostonBoston Scientific Corporation's Multimodal Guidance SystemAlso obtainedCE Mark,It is expected to begin distribution in early next year.

The main function of the system is performed by AI software known as Automatic Lesion Assessment, which automates critical procedural steps and provides precise vessel measurements. The system also reduces the procedure time for acquiring IVUS images, offering increased speed. Additionally, it enhances guidance through physiological mapping, providing physicians with a roadmap for treating diseased coronary arteries.

Lance Bates, President of Interventional Cardiology at Boston Scientific Corporation, stated: "We are excited to introduce the next-generation Avvigo+ Multimodal Guidance System to U.S. clinicians. Building on the foundation of the Avvigo Guidance System II, this system offers rapid, intuitive, and accurate lesion assessment capabilities for percutaneous coronary intervention. Following the updated ACC guidelines that include the use of intracoronary imaging during PCI, we believe this enhanced automated tool will help physicians optimize procedures and deliver better outcomes for patients with coronary artery disease."

# About Boston Scientific

Boston Scientific was founded in 1979, with its headquarters in Natick, Massachusetts, USA. It is a global leading medical technology company. In 1997, Boston Scientific entered China, establishing branches and research centers in Beijing, Shanghai, and Guangzhou. The company's headquarters in China is located in Shanghai. Boston Scientific has more than 17,000 products and has been granted over 16,000 authorized patents worldwide. In May 1992, Boston Scientific successfully went public on the New York Stock Exchange. In 2013, Boston Scientific’s R&D investment reached 861 million US dollars, making it one of the medical device companies with the highest R&D investment globally.

On April 26, Boston Scientific Corporation announced its financial results for the first quarter of 2023, with net sales of $3.389 billion, representing an organic growth of 14% compared to the same period last year. Both business segments achieved net sales growth, with the medical surgical business growing organically by 13.4% and the cardiovascular business by 14.4% compared to the same period last year.

Overseas Cardiovascular Devices:

Products of Chinese Cardiovascular Companies: